Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region – Global Forecast to 2025

Table of Contents

1.... INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET DEFINITION
1.3             MARKET SCOPE
1.4             YEARS CONSIDERED FOR THE STUDY
1.5             CURRENCY
1.6             STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1             RESEARCH DATA
2.2             SECONDARY DATA
2.2.1              SECONDARY SOURCES.. 25
2.3             PRIMARY DATA
2.3.1              KEY DATA FROM PRIMARY SOURCES
2.4             MARKET SIZE ESTIMATION
2.4.1              BOTTOM-UP APPROACH
2.4.2              GROWTH FORECAST. 28
2.4.3              TOP-DOWN APPROACH.. 28
2.5             MARKET BREAKDOWN AND DATA TRIANGULATION
2.6             ASSUMPTIONS FOR THE STUDY
2.7             LIMITATIONS

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1             BIOSIMILARS MARKET OVERVIEW
4.2             NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019
4.3             GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET

5.... REGULATORY OUTLOOK

5.1             NORTH AMERICA
5.1.1              US
5.1.2              CANADA
5.2             EUROPE
5.3             ASIA PACIFIC
5.3.1              CHINA
5.3.2              INDIA
5.3.3              JAPAN
5.3.4              SOUTH KOREA
5.3.5              AUSTRALIA
5.4             REST OF THE WORLD
5.4.1              BRAZIL
5.4.2              MEXICO
5.4.3              ARGENTINA
5.4.4              SAUDI ARABIA

6.... MARKET OVERVIEW

6.1             INTRODUCTION
6.2             MARKET DYNAMICS
6.2.1              DRIVERS
6.2.1.1            INCREASING DEMAND FOR BIOSIMILAR DRUGS
6.2.1.2            RISING INCIDENCE OF CHRONIC DISEASES
6.2.2              RESTRAINTS
6.2.2.1            COMPLEXITIES IN MANUFACTURING
6.2.2.2            RESISTANCE FROM BIOLOGIC MANUFACTURERS
6.2.3              OPPORTUNITIES
6.2.3.1            EMERGING MARKETS
6.2.3.2            NEW INDICATIONS AND THE PATENT EXPIRY OF BIOLOGIC PRODUCTS.. 45
6.2.4              CHALLENGES
6.2.4.1            STRINGENT REGULATORY REQUIREMENTS
6.2.5              TRENDS
6.2.5.1            COLLABORATIONS FOR BIOSIMILAR RESEARCH AND CLINICAL TRIALS

7.... BIOSIMILARS MARKET, BY PRODUCT

7.1             INTRODUCTION
7.2             MONOCLONAL ANTIBODIES
7.2.1              INFLIXIMAB
7.2.1.1            INFLIXIMAB ACCOUNTED FOR THE LARGEST SHARE OF THE MONOCLONAL ANTIBODIES MARKET
7.2.2              RITUXIMAB
7.2.2.1            RISING INCIDENCE OF AUTOIMMUNE DISEASES AND CANCER ARE KEY DRIVERS OF MARKET GROWTH
7.2.3              TRASTUZUMAB
7.2.3.1            RISING INCIDENCES OF CANCER WILL DRIVE MARKET GROWTH
7.2.4              ADALIMUMAB
7.2.4.1            ADALIMUMAB WILL REGISTER THE HIGHEST CAGR IN THE MONOCLONAL ANTIBODIES MARKET
7.2.5              OTHER MONOCLONAL ANTIBODIES
7.3             INSULIN
7.3.1              INCREASING INCIDENCE OF DIABETES WILL SUPPORT MARKET GROWTH
7.4             GRANULOCYTE COLONY-STIMULATING FACTOR
7.5             ERYTHROPOIETIN
7.5.1              RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH
7.6             RECOMBINANT HUMAN GROWTH HORMONE
7.6.1              MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS
7.7             ETANERCEPT
7.7.1              APAC MARKET FOR ETANERCEPT WILL SHOW THE HIGHEST GROWTH IN THE FORECAST PERIOD
7.8             FOLLITROPIN
7.8.1              INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT WILL DRIVE MARKET GROWTH
7.9             TERIPARATIDE
7.9.1              INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAIN GROWTH DRIVER FOR THIS MARKET
7.10          INTERFERONS
7.10.1            MARKET GROWTH IS SUPPORTED BY THE RISING INCIDENCE OF INFECTIOUS DISEASES
7.11          ENOXAPARIN SODIUM
7.11.1            WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS.. 61
7.12          GLUCAGON
7.12.1            SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET
7.13          CALCITONIN
7.13.1            INCREASING INCIDENCE OF OSTEOPOROSIS WILL DRIVE THE MARKET

8.... BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING

8.1             INTRODUCTION
8.2             IN-HOUSE MANUFACTURING
8.2.1              COST-EFFECTIVENESS MAKES IN-HOUSE MANUFACTURING HIGHLY PREFERABLE FOR MOST MARKET PLAYERS. 64
8.3             CONTRACT MANUFACTURING
8.3.1              OUTSOURCING PRODUCTION ENABLES COMPANIES TO FOCUS ON CORE COMPETENCY AND PROVIDES COST-BENEFITS.. 65

9.... BIOSIMILARS MARKET, BY INDICATION

9.1             INTRODUCTION
9.2             ONCOLOGY
9.2.1              RISING BURDEN OF CANCER AND GROWING INCIDENCE HAVE DRIVEN DEMAND FOR BIOSIMILARS
9.3             CHRONIC DISEASES
9.3.1              HIGH EFFICACY OF BIOSIMILARS HAS DRIVEN RESEARCH INTO APPLICATIONS IN CHRONIC DISEASE TREATMENT. 71
9.4             AUTOIMMUNE DISEASES
9.4.1              GROWING RESEARCH ACTIVITY FOR AUTOIMMUNE DISEASE INDICATIONS WILL FAVOR MARKET GROWTH
9.5             BLOOD DISORDERS
9.5.1              POSSIBILITY OF COST-REDUCTIONS IN BLOOD DISORDER TREATMENT WILL SUPPORT MARKET DEMAND FOR BIOSIMILARS
9.6             GROWTH HORMONE DEFICIENCY
9.6.1              GROWING CASES OF GH DEFICIENCY DRIVES DEMAND FOR BIOSIMILARS
9.7             INFECTIOUS DISEASES
9.7.1              ASIA PACIFIC SHOWS HIGHEST DEMAND FOR BIOSIMILARS IN THIS SEGMENT
9.8             OTHER INDICATIONS

10.. BIOSIMILARS MARKET, BY REGION

10.1          INTRODUCTION
10.2          EUROPE
10.2.1            UK
10.2.1.1          THE UK HOLDS THE LARGEST SHARE OF THE BIOSIMILARS MARKET IN EUROPE
10.2.2            FRANCE
10.2.2.1          RISING GERIATRIC POPULATION WILL DRIVE MARKET GROWTH
10.2.3            GERMANY
10.2.3.1          THE PRESENCE OF A FAVORABLE PRICING SYSTEM HAS SUPPORTED BIOSIMILAR ADOPTION IN GERMANY
10.2.4            ITALY
10.2.4.1          RISING GERIATRIC POPULATION IN ITALY WILL SUPPORT MARKET GROWTH.. 92
10.2.5            SPAIN
10.2.5.1          R&D INVESTMENTS FOR THE DEVELOPMENT OF INNOVATIVE DRUGS IS A KEY GROWTH DRIVER IN THE SPANISH MARKET
10.2.6            REST OF EUROPE
10.3          ASIA PACIFIC
10.3.1            INDIA
10.3.1.1          INDIA HOLDS THE LARGEST SHARE OF THE APAC MARKET
10.3.2            CHINA
10.3.2.1          CHINA ACCOUNTS FOR THE SECOND-LARGEST SHARE OF THE APAC MARKET
10.3.3            SOUTH KOREA
10.3.3.1          RISING INCIDENCES OF CHRONIC DISEASES ARE EXPECTED TO DRIVE THE MARKET IN SOUTH KOREA
10.3.4            JAPAN
10.3.4.1          GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE MARKET IN JAPAN
10.3.5            AUSTRALIA
10.3.5.1          INCREASING NUMBER OF PRODUCT LAUNCHES WILL DRIVE MARKET GROWTH
10.3.6            REST OF ASIA PACIFIC
10.4          NORTH AMERICA
10.4.1            US
10.4.1.1          US WILL DOMINATE THE NORTH AMERICAN BIOSIMILARS MARKET
10.4.2            CANADA
10.4.2.1          INCREASING INCIDENCES OF CHRONIC DISEASES WILL DRIVE MARKET GROWTH IN CANADA
10.5          LATIN AMERICA
10.5.1            RISING INCIDENCES OF CANCER WILL DRIVE MARKET GROWTH
10.6          MIDDLE EAST AND AFRICA
10.6.1            FAVORABLE HEALTHCARE REFORMS AND INFRASTRUCTURAL DEVELOPMENT WILL FAVOR MARKET GROWTH

11.. COMPETITIVE LANDSCAPE

11.1          OVERVIEW
11.2          MARKET SHARE ANALYSIS, 2018
11.3          COMPETITIVE SCENARIO
11.3.1            PRODUCT LAUNCHES AND APPROVALS
11.3.2            PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
11.3.3            ACQUISITIONS
11.3.4            EXPANSIONS
11.4          COMPETITIVE LEADERSHIP MAPPING (2018)
11.4.1            VENDOR INCLUSION CRITERIA
11.4.2            VISIONARY LEADERS.. 141
11.4.3            INNOVATORS
11.4.4            DYNAMIC DIFFERENTIATORS
11.4.5            EMERGING COMPANIES

12.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, PRODUCT PIPELINE & MNM VIEW)*
12.1          SANDOZ
12.2          PFIZER
12.3          ELI LILLY
12.4          TEVA PHARMACEUTICAL
12.5          CELLTRION
12.6          BIOCON
12.7          AMGEN
12.8          SAMSUNG BIOLOGICS
12.9          MYLAN
12.10        DR. REDDY’S LABORATORIES
12.11        STADA ARZNEIMITTEL AG
12.12        COHERUS BIOSCIENCES
12.13        BIOCAD
12.14        AMEGA BIOTECH
12.15        PROBIOMED
12.16        BOEHRINGER INGELHEIM
12.17        APOTEX
12.18        FRESENIUS KABI
12.19        GEDEON RICHTER
12.20        MABXIENCE
*DETAILS ON BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, PRODUCT PIPELINE & MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES

13.. APPENDIX

LIST OF TABLES

TABLE 1              STATUS OF REGULATORY PATHWAY IN NORTH AMERICA
TABLE 2              SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
TABLE 3              STATUS OF REGULATORY PATHWAY IN THE ASIA PACIFIC
TABLE 4              STATUS OF REGULATORY PATHWAY IN ROW COUNTRIES
TABLE 5              LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
TABLE 6              MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017–2020)
TABLE 7              BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 8              BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 50
TABLE 9              US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (UNITS)
TABLE 10            BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 11            BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 12            BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 13            BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 14            BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2018–2025 (USD MILLION)
TABLE 15            BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 16            BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 17            LIST OF APPROVED BIOSIMILARS FOR G-CSF
TABLE 18            BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018–2025 (USD MILLION)
TABLE 19            LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
TABLE 20            BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 21            BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018–2025 (USD MILLION)
TABLE 22            BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2018–2025 (USD MILLION)
TABLE 23            BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 24            BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2018–2025 (USD MILLION)
TABLE 25            BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 26            BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM, BY REGION, 2018–2025 (USD MILLION)
TABLE 27            BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2018–2025 (USD MILLION)
TABLE 28            BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2018–2025 (USD MILLION)
TABLE 29            BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 30            BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING, BY REGION, 2016–2023 (USD MILLION)
TABLE 31            BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2018–2025 (USD MILLION)
TABLE 32            BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 33            BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS, 2017–2019
TABLE 34            BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2018–2025 (USD MILLION)
TABLE 35            BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2018–2025 (USD MILLION)
TABLE 36            BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES, 2017–2019
TABLE 37            BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2018–2025 (USD MILLION) 73
TABLE 38            BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 39            BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2018–2025 (USD MILLION)
TABLE 40            BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD MILLION) 76
TABLE 41            BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2018–2025 (USD MILLION)
TABLE 42            BIOSIMILARS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 43            LIST OF BIOSIMILARS APPROVED IN EUROPE
TABLE 44            EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 45            EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 46            EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 47            EUROPE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 48            EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 49            LIST OF BIOSIMILARS IN THE UK
TABLE 50            UK: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 51            UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 52            UK: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 53            UK: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 54            FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 55            FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 56            FRANCE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 57            FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 58            LIST OF BIOSIMILARS APPROVED IN GERMANY
TABLE 59            GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 60            GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 61            GERMANY: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 62            GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 63            ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 64            ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 65            ITALY: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 66            ITALY: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 67            SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 68            SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 69            SPAIN: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 70            SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 71            ROE: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 72            ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 73            ROE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 74            ROE: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 75            ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 101
TABLE 76            ASIA PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 77            ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 78            ASIA PACIFIC: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 79            ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 80            BIOSIMILARS APPROVED AND MARKETED IN INDIA
TABLE 81            INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 82            INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 83            INDIA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 84            INDIA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 85            BIOSIMILARS APPROVED IN CHINA
TABLE 86            CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 87            CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 88            CHINA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 89            CHINA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 90            LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
TABLE 91            SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 111
TABLE 92            SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 93            SOUTH KOREA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 94            SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 95            LIST OF BIOSIMILARS APPROVED IN JAPAN
TABLE 96            JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 97            JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 98            JAPAN: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 99            JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 100          LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
TABLE 101          AUSTRALIA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 102          AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 103          AUSTRALIA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 104          AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 105          LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
TABLE 106          LIST OF BIOSIMILARS APPROVED IN MALAYSIA
TABLE 107          LIST OF BIOSIMILARS APPROVED IN SINGAPORE
TABLE 108          ROAPAC: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 109          ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 110          ROAPAC: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 111          ROAPAC: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 112          NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 123
TABLE 113          NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 114          NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 115          NORTH AMERICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 116          NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 117          LIST OF BIOSIMILARS APPROVED IN THE US
TABLE 118          US: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 119          US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 120          US: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 121          US: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 122          LIST OF BIOSIMILARS APPROVED IN CANADA
TABLE 123          CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
TABLE 124          CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION)
TABLE 125          CANADA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 126          CANADA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 127          LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA
TABLE 128          LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 133
TABLE 129          LATIN AMERICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 130          LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)
TABLE 131          MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 135
TABLE 132          MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018–2025 (USD MILLION)
TABLE 133          MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2018–2025 (USD MILLION)

 

FIGURE 1            RESEARCH DESIGN
FIGURE 2            BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3            MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
FIGURE 4            TOP-DOWN APPROACH
FIGURE 5            DATA TRIANGULATION METHODOLOGY
FIGURE 6            BIOSIMILARS MARKET, BY PRODUCT, 2020 VS. 2025 (USD BILLION)
FIGURE 7            BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2020 VS. 2025 (USD BILLION)
FIGURE 8            BIOSIMILARS MARKET, BY INDICATION, 2020 VS. 2025 (USD MILLION)
FIGURE 9            BIOSIMILARS MARKET, BY REGION, 2020 VS. 2025 (USD BILLION)
FIGURE 10          RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET
FIGURE 11          INSULIN HELD LARGEST MARKET SHARE IN 2019
FIGURE 12          CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 13          BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
FIGURE 14          INCREASING GERIATRIC POPULATION, BY REGION, 2019 VS. 2050
FIGURE 15          GLOBAL INCIDENCE OF DIABETES, BY REGION, 2019, 2030, 2045
FIGURE 16          ONCOLOGY SEGMENT TO DOMINATE THE BIOSIMILARS MARKET
FIGURE 17          ARTICLES PUBLISHED ON BIOSIMILARS FOR ONCOLOGY, 2010–2018
FIGURE 18          ARTICLES PUBLISHED ON BIOSIMILARS FOR CHRONIC DISEASES, 2010–2018
FIGURE 19          ARTICLES PUBLISHED ON BIOSIMILARS FOR AUTOIMMUNE DISEASES, 2010–2018
FIGURE 20          ARTICLES PUBLISHED ON BIOSIMILARS FOR BLOOD DISORDERS, 2010–2018
FIGURE 21          ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD
FIGURE 22          EUROPE: BIOSIMILARS MARKET SNAPSHOT
FIGURE 23          ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE UK, 2010–2018
FIGURE 24          ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN FRANCE, 2010–2018
FIGURE 25          ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN GERMANY, 2010–2018
FIGURE 26          ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN ITALY, 2011–2019
FIGURE 27          ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN SPAIN, 2010–2018
FIGURE 28          ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
FIGURE 29          ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE US, 2010–2018
FIGURE 30          PROJECTED INCREASE IN CANCER INCIDENCE IN CANADA
FIGURE 31          ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN CANADA, 2010–2018
FIGURE 32          KEY DEVELOPMENTS OF MAJOR PLAYERS FROM 2017 TO 2020
FIGURE 33          GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
FIGURE 34          MNM DIVE-VENDOR COMPARISON MATRIX: BIOSIMILARS MARKET
FIGURE 35          SANDOZ: COMPANY SNAPSHOT
FIGURE 36          PFIZER: COMPANY SNAPSHOT
FIGURE 37          ELI LILLY: COMPANY SNAPSHOT
FIGURE 38          TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
FIGURE 39          CELLTRION: COMPANY SNAPSHOT
FIGURE 40          BIOCON: COMPANY SNAPSHOT
FIGURE 41          AMGEN: COMPANY SNAPSHOT
FIGURE 42          SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
FIGURE 43          MYLAN: COMPANY SNAPSHOT
FIGURE 44          DR. REDDY’S LABORATORIES: COMPANY SNAPSHOT
FIGURE 45          STADA ARZNEIMITTEL: COMPANY SNAPSHOT
FIGURE 46          BOEHRINGER INGELHEIM: COMPANY SNAPSHOT

当レポートのプレスリリースは発行されておりません。